Similar variability was seen across OPRM1, PPP6C, and FURIN in drug repurposing analyses. While OPRM1 is the known target of more than 100 drugs and compounds, FURIN is the target of one approved drug (pirfenidone), and PPP6C is not a target of any known drug or compound However, FURIN is the target of more than 80 compounds and the PPP6C protein has a 94% likelihood of being ligandable. Should these novel gene associations be validated in subsequent studies they appear to be potentially important drug development targets.
